Prosecutors investigating Samsung BioLogics' alleged accounting fraud have sought arrest warrants for executives and employees of its subsidiary Samsung Bioepis on charges of destroying evidence.
The Seoul Central District Prosecutors' Office on April 25 sought arrest warrants for Samsung Bioepis director A and manager B on charges of falsifying and destroying evidence, and violating the external audit law.
They are under suspicion that Samsung BioLogics committed intentional accounting fraud by changing accounting standards for its subsidiaries, including Samsung Bioepis, in 2015.
In November last year, the Securities and Futures Commission filed a complaint against Samsung BioLogics for intentional accounting fraud. Prosecutors raided the headquarters of Samsung BioLogics and Samsung Bioepis.
In March, it raided about 10 offices of related officials, including the data center of Samsung SDS and the office of Samsung C&T's construction unit in Sangil-dong, Seoul.
It also conducted a search and seizure of the U.S.-based multinational investment bank Goldman Sachs, which was the listing organizer at the time when Samsung Bioepis, a subsidiary of Samsung BioLogics, pushed for the Nasdaq listing.
After summoning and questioning Samsung Bioepis executives and employees, including CEO Goh Han-seung, the prosecution is reportedly planning to question Samsung Group's order and reporting system over accounting fraud after securing the custody of executives and employees suspected of having deeply involved in destroying evidence.
